Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study - PubMed
4 hours ago
- #Blastema Volume
- #Wilms Tumor
- #Clinical Outcomes
- Residual Absolute Volume of Blastema (AVB) is a significant predictor of clinical outcomes in Wilms Tumor (WT) patients.
- The study analyzed data from 3,459 patients with unilateral WT treated between 2001 and 2018 in the SIOP WT 2001 study.
- AVB thresholds were identified for different WT subtypes: ≥20 mL for intermediate-/low-risk WT (IRWT/LRWT), ≥100 mL for high-risk WT (HRWT), and ≥10 mL for metastatic WT (stage IV).
- Patients exceeding these AVB thresholds had significantly worse event-free survival (EFS) and overall survival (OS).
- In stage II to III IRWT patients with AVB ≥20 mL, those treated with doxorubicin had superior EFS compared to those without.
- AVB is recommended as a stratification criterion in future SIOP-RTSG protocols to identify patients who may benefit from intensified therapy.